Day One

• A multi-active immunotherapy designed to address multi-system age-related decline across metabolic, muscular, and functional health
• Metabolic benefits observed in Phase 2a double-blind, randomized clinical trial include reversal of pre-diabetes, reduction of liver fat, and improvements in body composition
• Muscle and functional benefits include improved gait speed, muscle strength, quality of life, and physical activity, supporting a comprehensive approach to healthy aging

• Advancing next-generation amylin agonists to enhance appetite control and satiety, unlocking greater weight loss efficacy beyond traditional GLP-1 pathways
• Identifying the patients most likely to benefit from amylin-based therapies by evaluating clinical evidence, response patterns and emerging opportunities for targeted treatment selection
• Optimizing amylin-GLP-1 combination strategies to maximize weight loss outcomes while improving tolerability and supporting long-term treatment adherence

• Demonstrating durable improvements in glycemic control across both type 1 and type 2 diabetes, and supporting the potential restoration of beta-cell function and improvement in mass
• Exploring how icovamenib could complement GLP-1 therapies to deliver improved metabolic outcomes across diabetes and obesity populations
• Uncovering translational evidence of muscle preservation, fat reduction, and enhanced GLP-1 pathway activity to expand icovamenib’s potential beyond glucose management

Join our speed networking session tailored for Obesity & Weight Loss Therapeutics professionals like yourselves, to connect with fellow industry peers to facilitate rapid yet meaningful exchanges of insights and expertise. Elevate your networking experience during this session designed for impactful connections within the space.

• Combining a novel oral therapy with GLP-1s to deliver additional weight loss while improving muscle strength throughout treatment
• Targeting the underlying drivers of muscle regeneration to support healthy weight loss and functional independence
• Enhancing muscle quality and repair alongside weight reduction to improve long-term outcomes for older adults with obesity

AMRA

• Advancing clinical development, sharing Phase 1 safety and tolerability findings, and the transition into longer-duration Phase 1b studies evaluating ongoing efficacy
• Exploring a differentiated oral GLP-1 highlighting new preclinical and clinical insights into a novel allosteric GLP-1 mechanism, including its distinctive molecular profile and encouraging GI tolerability, with no meaningful nausea or vomiting observed to date
• Preserving muscle beyond weight loss Exploring the AMPK activator program in combination with GLP-1 therapy and its potential to support muscle preservation, alongside the next development milestones for both programs

• Examining how poor adherence and early treatment discontinuation contribute to suboptimal outcomes and rapid weight regain
• Exploring whether continuous, long-acting drug exposure can improve tolerability and persistence by reducing fluctuations associated with missed doses
• Evaluating the potential of reversible implant-based therapies to deliver durable efficacy with minimal patient burden while maintaining treatment flexibility and control

Curi Bio

• How do patient preferences differ across daily oral, weekly injectable, monthly injectable, and long acting therapies, and what factors most influence modality selection?
• How should developers balance the convenience of long-acting treatments against the safety and practical considerations associated with pregnancy, adverse events, surgical procedures, and changing patient circumstances?
• What is the optimal dosing frequency, to maximize adherence and persistence while sufficient flexibility for dose adjustments, treatment interruptions and treatment discontinuation when needed?

Take this opportunity to showcase your latest research and innovations with your peers and understand the strategies of your fellow obesity experts.

• Designing a differentiated Triple-G agonist by optimizing GLP-1, GIP, and glucagon receptor potency ratios to balance tolerability, metabolic efficacy, and weight loss potential
• Applying Protagonist’s oral peptide discovery platform to engineer PN-477 as both an oral and subcutaneous candidate, overcoming traditional challenges in peptide stability, potency, and delivery
• Translating molecular design into preclinical performance through receptor pharmacology, PK profiling, and in vivo efficacy studies demonstrating robust weight-loss potential across multiple animal models

Gubra

• Novel mechanism combines fat-specific weight loss and muscle preservation in a single, convenient pill
• Preclinical data demonstrate favorable body composition and improvements in brain and metabolic health
• Opportunities for improved tolerability and expanded treatment options for obesity patients